Q2 EPS Forecast for Agilent Technologies Reduced by Analyst

Agilent Technologies, Inc. (NYSE:A) – Leerink Partnrs cut their Q2 2025 earnings per share estimates for Agilent Technologies in a research note issued to investors on Wednesday, December 18th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $1.32 for the quarter, down from their prior forecast of $1.33. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.56 per share. Leerink Partnrs also issued estimates for Agilent Technologies’ Q4 2025 earnings at $1.56 EPS and FY2027 earnings at $6.63 EPS.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $1.41 by $0.05. The business had revenue of $1.70 billion for the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The company’s revenue was up .8% compared to the same quarter last year. During the same period last year, the business earned $1.38 EPS.

A number of other equities research analysts have also recently commented on the company. Sanford C. Bernstein decreased their price target on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a research note on Tuesday, November 26th. JPMorgan Chase & Co. lowered their target price on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research note on Tuesday, November 26th. Stifel Nicolaus reissued a “buy” rating and set a $151.00 target price on shares of Agilent Technologies in a research report on Monday, August 26th. StockNews.com cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, November 26th. Finally, Citigroup boosted their price objective on shares of Agilent Technologies to $165.00 and gave the company a “buy” rating in a report on Thursday. One analyst has rated the stock with a sell rating, seven have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $143.62.

Agilent Technologies Stock Up 1.0 %

Agilent Technologies stock opened at $134.51 on Friday. Agilent Technologies has a 1-year low of $124.16 and a 1-year high of $155.35. The business has a fifty day moving average price of $135.85 and a 200-day moving average price of $136.48. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.09 and a quick ratio of 1.58. The stock has a market capitalization of $38.65 billion, a price-to-earnings ratio of 30.43, a PEG ratio of 4.48 and a beta of 1.07.

Institutional Investors Weigh In On Agilent Technologies

A number of institutional investors have recently modified their holdings of the business. Massachusetts Financial Services Co. MA increased its holdings in Agilent Technologies by 3.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,589,874 shares of the medical research company’s stock worth $2,314,784,000 after acquiring an additional 525,214 shares in the last quarter. State Street Corp raised its position in shares of Agilent Technologies by 1.2% during the 3rd quarter. State Street Corp now owns 12,819,897 shares of the medical research company’s stock worth $1,903,498,000 after purchasing an additional 158,175 shares during the last quarter. Geode Capital Management LLC lifted its stake in Agilent Technologies by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 6,948,679 shares of the medical research company’s stock valued at $1,028,241,000 after buying an additional 30,610 shares in the last quarter. Van ECK Associates Corp boosted its holdings in Agilent Technologies by 6.6% in the 3rd quarter. Van ECK Associates Corp now owns 2,976,905 shares of the medical research company’s stock worth $442,011,000 after buying an additional 183,716 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Agilent Technologies by 4.8% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,948,536 shares of the medical research company’s stock worth $437,799,000 after buying an additional 136,184 shares in the last quarter. 87.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Agilent Technologies

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the transaction, the senior vice president now owns 40,011 shares of the company’s stock, valued at approximately $5,801,595. The trade was a 19.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.33% of the stock is currently owned by corporate insiders.

Agilent Technologies Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 22nd. Investors of record on Tuesday, December 31st will be given a dividend of $0.248 per share. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.24. This represents a $0.99 annualized dividend and a yield of 0.74%. The ex-dividend date is Tuesday, December 31st. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.40%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.